Stock Notes

Glenmark Pharmaceuticals

Every Finvezto stock note on Glenmark Pharmaceuticals, dated and newest first. Coverage spans pharma.

2 notes and counting
02 Jul 2026
Glenmark's subsidiary Glenmark Specialty is advancing a multi-country Phase 3 trial of Trastuzumab rezetecan, a HER2-targeted antibody drug conjugate, for platinum-resistant ovarian cancer.
India will be the first of Glenmark's licensed markets to start patient enrollment after DCGI approval. Australia and South Korea will follow, subject to approvals. It deepens Glenmark's oncology pipeline.
11 Jun 2026
Glenmark launched Winlevi, its acne cream clascoterone, across key European markets including the Nordics, Spain and Central Europe, its first European NCE launch.
Winlevi is the first new topical acne mechanism in over 40 years, licensed from Cosmo Pharmaceuticals, opening a direct-sales beachhead in Europe for Glenmark.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.